Skip to main content
OpenTrials
Completed

NCT Number: NCT03766373

Evaluation of Safety and Reduction of Ear Pain in Adults With Acute Otitis Media and Reduction of Ear Pain in Adults With Acute Otitis Media

The purpose of this study is to evaluate the Safety and Reduction of Ear Pain in Adults with Acute Otitis Media.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

US Clinical Research Group, LLC., Bellflower, California, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

includes but is not limited to:

  • AOM diagnosis with moderate to severe bulging of the TM and recent (< 48 hours [h]) onset of ear pain.
  • Moderate to severe ear pain in the affected ear(s), defined as a score of ≥ 5 (on a scale of 0 10) on the NRS 11 as evaluated by the subject at Screening.
  • Generally good health (other than AOM) as determined by evaluation of medical history and physical examination at Screening.
  • Negative urine pregnancy test at Screening for all female subjects of childbearing potential.
  • Able to read and sign written informed consent prior to study participation.

Exclusion criteria

includes but is not limited to:

  • Presence of a perforated TM at Screening or had a perforated TM within 6 months (mo) prior to Screening as determined by medical history
  • Subjects with tympanostomy tubes
  • Acute or chronic otitis externa
  • Chronic otitis media defined as confirmed presence of middle ear effusion for 12 weeks or longer
  • Disorders with decreased mucociliary clearance or higher viscosity of the mucous (eg, cystic fibrosis, primary ciliary dyskinesia, Kartagener's syndrome)
  • Clinically relevant blockage of 1 or both nasal passages, as determined by the investigator's medical judgment
  • Permanent hearing loss irrespective of otitis media
  • Subjects with medical conditions that may affect interpretation of the safety or efficacy of study drug as determined by the investigator's medical judgment
  • Subjects with craniofacial abnormalities (eg, cleft palate, Down's Syndrome)
  • Subjects with erythema of the TM without other evidence of otitis media
  • Seborrheic dermatitis involving the affected external ear canal or pinna
  • Use of medications with known vasoconstrictive properties (eg, decongestants [Afrin®, Sudafed®]) currently or within 2 h prior to Screening
  • Use of oral analgesics < 2 h prior to Screening or Baseline (oral analgesics > 2 h are permitted as long as ear pain criteria are met per Inclusion Criteria)

Treatment and study plan

Drug: OP0201 20mg

Combination Product

OP0201

Drug: Placebo 0mg

Combination Product

Placebo

Primary outcomes

  1. Number of Participants With Adverse Events

    Time frame: 1 Day

Sponsors and collaborators

Lead sponsor

Novus Therapeutics, Inc

Industry

Registry information

Official study title

Evaluation of Safety and Reduction of Ear Pain in Adults With Acute Otitis Media

Important dates

Study start
2019
Primary completion
2019
Study completion
2019
First posted
Dec 6, 2018
Registry last updated
Dec 5, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.